Articles

Keep up with our latest news and industry insights
by exploring the articles section

Promotional banner split into two halves: left shows London skyline with Big Ben and Houses of Parliament at sunset, advertising the 17th Annual World ADC London 2027 event from March 8-11 with a 'Meet us' button; right side shows New York City skyline with Brooklyn Bridge at sunset promoting DCAT Week from March 15-18, 2027, also with a 'Meet us' button.

The Hidden Variable: How Payload–Linker Chemistry Shapes the Future of ADC Therapy

Two ADCs can share the same antibody, target and payload yet behave differently, often due to the linker and payload–linker design.

The rise of precision oncology

The Rise of Precision Oncology

The Market Shift Reshaping Oncology Drug Landscape

Polpharma API to support Celon Pharma’s ADC development program with payload–linker GMP manufacturing

Polpharma API to support Celon Pharma’s ADC development program with payload–linker GMP manufacturing

Polpharma API selected by Celon Pharma to develop and manufacture a payload-linker for its ADC development program.

We are moving SMA care forward

Understanding the Oligonucleotide Market: A Foundation for Next‑Generation API Capabilities

Learn why the oligonucleotides are becoming one of the fastest‑growing API segments.

Polpharma API CDMO HP API Virtual Tour

Digital Twin at Polpharma API: Turning Manufacturing Data into Predictable Value

Our change from reactive to preventive manufacturing.

We are moving SMA care forward

Broadening Access: How Generic APIs Are Shaping the Future of SMA Treatment

Discover how generic APIs are helping turn medical innovation in SMA into broader, global access to treatment.

Polpharma API CDMO solubility article

Rising to the Solubility Challenge: Collaborative Solutions in API Development

Water solubility is one of the crucial challenges in API development. See how it can be tackled.

Polpharma API CDMO ADC article

Antibody-Drug Conjugates (ADCs): Revolutionizing Cancer Treatment

Explore the potential of this groundbreaking innovation.

Polpharma API CDMO environmental responsibility

Polpharma Group's environmental responsibility

In the last couple of years, we conducted a variety of initiatives and programmes aimed at making our business more sustainable.

Polpharma API CDMO oncology article

Rising Prevalence of Cancer and Its Impact on the HP API Market

An inside look into the growing demand for HPAPIs in oncology

Polpharma API CDMO breast cancer article

An Overview of Breast Cancer: Understanding Risks, Treatments, and Market Trends

Polpharma API CDMO HPAPI facility

Polpharma's HP API facility is live!

On September 18th, 2024, we launched the new state-of-the-art manufacturing facility.

Polpharma API CDMO nistrosamine article

Addressing Nitrosamine Risks in Pharmaceutical Manufacturing

Get a behind-the-scenes look into how we deal with Nitrosamines control.

Polpharma API CDMO diabetology article

A Comprehensive Overview and Prognosis of the Diabetes Market

Read about diabetes types, methods of treatment and market overview.

Polpharma API CDMO waters nitrosamine equipment

Tackling the Dynamic Challenge of N-nitrosamines Control with High Performance Analytical Instrumentation

We partnered with Waters, , a leading provider of lab equipment, to address the issue of Nitrosamines.

First CADIFA certification from ANVISA for Etodolac

We're proud to announce the milestone of our presence on the LATAM market.

Polpharma API CDMO High Potent Kilo Lab

KiloLab Laboratory: strategic milestone achieved!

KiloLab Laboratory - a development and production in a kilogram scale - has been launched at Polpharma API.

Polpharma API CDMO & Ryvu therapeutics project

Ryvu Therapeutics and Polpharma sign two agreements in the area of RVU120 active substance (API) production for Phase II clinical trials

Polpharma API takes on a CDMO project for Ryvu Therapeutics.

Cryogenic infrastructure at Polpharma API CDMO

Cryogenic infrastructure at API facility

New installation at Polpharma provides the best quality of products

Polpharma API CDMO liophilization technology

Liophilization: What does a strawberry have in common with Polpharma API?

On November 2022, at Polpharma API Plant, we implemented freeze-drying machine!

Polpharma API CDMO HPAPI isolators

Polpharma’s strategic investment in HP API facility, the first of this kind in Poland

We are making a strategic investment in a HPAPI facility, which will make Poland a strong pillar of the European pharmaceutical industry.

Polpharma API CDMO laboratory

Safe approach in delivering nitrosamine-free API products

Karina Boszko, head of API Regulatory Affairs and Customer Technical Support Department, explains how we undertake this challenge.

Polpharma API CDMO laboratory

Polpharma partners with Pikralida biopharmaceutical start-up

Polpharma has established cooperation with Pikralida, a biopharmaceutical start-up that is working on a breakthrough therapeutic solution

Polpharma API CDMO Business Unit transformation

September 2019 was the date when the transformation process started in the API Business Unit of Polpharma.

Learn about the transformation process at Polpharma API, including how we use KPIs to facilitate rapid and correct decisions.

Digital transformation at Polpharma API CDMO

Searching for new, better, and innovative solutions. Digital Transformation at Polpharma API.

Learn about how digital transformation is impacting Polpharma API and the people who power it.

Nitrosamines risk evaluation article

Polpharma API completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.

EMA’s CHMP requested on, that MAHs review human medicines with chemically synthesized APIs for the possible presence of nitrosamines.

Polpharma API CDMO PSD equipment

Why particles size is important in pharmaceutical industry? Is it really problematic?

Learn about the importance of particles size in the pharmaceutical industry and how to control it.

Have a question?

Our specialists will be happy to guide you through our cooperation process.